U.S. Border Patrol said they recently arrested a woman who walked across a railway bridge from Niagara Region into Buffalo, NY in what officials are describing as an apparent human smuggling attempt.
A migrant gang based in New Jersey is sneaking dozens if not hundreds of immigrants across the more porous Canadian border, charging hefty fees to smuggle them into the US, a new report says.
UC San Francisco’s Thomas G. Martin, MD, a leading expert in blood cancers, has received a grant of nearly $4.6 million from the California Institute of Regenerative Medicine to produce a CAR T cell therapy for multiple myeloma, the second most common malignancy among blood cancers.
Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.
Jeffrey V. Matous, MD, highlights takeaways from the phase 3 IKEMA trial and notes the benefits of administering CAR T-cell therapy in earlier lines, as evidenced in primary results from the phase 3 CARTITUDE-4 trial.